GenWay Biotech Announces Changes to Board of Directors
GenWay Biotech, a leading provider of protein and antibody solutions, today announced the appointment of Thomas Silberg, President and Chief Executive Officer of GenWay Biotech as Chairman of the Board, and Joseph Panetta, President and Chief Executive Officer (CEO) of BIOCOM and Robert Richard Garber, PhD, Drug Development Consultant as members of the Board of Directors. - November 14, 2013
GenWay Biotech Names Dr. Ruben Flores-Saaib Vice President of Custom and Catalog Services
GenWay Biotech announces Ruben Flores-Saaib, PhD as Vice President of Custom and Catalog Services assuming responsibilities for the Company's custom services and catalog business operating activities. - March 06, 2013
GenWay Biotech Launches Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011 First Multiple Biomarker Test to Predict Near Term MI
FirstMark, the diagnostic division of GenWay Biotech, Inc., today announced study results and the commercial launch of PREventTM. FirstMark PREvent is the first multiple biomarker test that accurately predicts near term (approximately 2-3 years) risk of myocardial infarction for suspected or confirmed coronary artery disease (CAD) patients. FirstMark PREvent is now available and will be targeted to primary care physicians and cardiologists. - November 24, 2011